NDAORALTABLET, FOR SUSPENSION
Lifecycle
Pre-Launch
Clinical Trials
20
Data completeness
2/8 — Basic
NEVIRAPINE (nevirapine) by Cipla is non-nucleoside reverse transcriptase inhibitors [moa].
Drug data last refreshed 18h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection. It works by binding to and inhibiting the reverse transcriptase enzyme, preventing viral replication. This oral tablet/suspension formulation is indicated as part of combination antiretroviral therapy.
PRE_LAUNCH
Pre-launch stage indicates a small, focused team building infrastructure for market entry in the competitive HIV treatment space.
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
Started Sep 2014
11 enrolled
HIV Infections
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
Started Aug 2014
46 enrolled
HIV-1
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Started Apr 2014
150 enrolled
HIV
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.
36 enrolled
HIV Infections
A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine
400 enrolled
HIV Infections
Worked on NEVIRAPINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.